Multiple silver linings in spite of a soft Q2 24
15/05/24 -"Coloplast reported softer than expected Q2 24 figures. However, with healthy organic growth, the miss reflected FX headwinds, and, hence, was not that worrisome. Importantly, growth was strong across ..."
Pages
62
Language
English
Published on
15/05/24
You may also be interested by these reports :
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...
29/05/26
Elekta’s Q4 results revealed an adjusted EBIT exceeding expectations, although sales fell short. The company offered qualitative guidance for ...
26/05/26
Piling up assets is no strategy
25/05/26
The modest TP reduction reflects downward revisions to DCF and NAV, driven by lower near-term earnings (as discussed in the ‘EPS’ section). While our ...